Geron Corporation’s Phase 3 Study on Imetelstat: A Potential Game-Changer for Myelofibrosis Treatment

Geron Corporation ((GERN)) announced an update on their ongoing clinical study.

Geron Corporation is conducting a Phase 3 clinical study titled A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor. The study aims to assess the overall survival of participants receiving imetelstat compared to those receiving the best available therapy, targeting patients with intermediate-2 or high-risk MF who have not responded to JAK-inhibitor treatment.

The study tests two interventions: Imetelstat, an experimental drug administered intravenously every 21 days, and Best Available Therapy (BAT), a non-JAK-inhibitor treatment selected by investigators. The goal is to determine which treatment offers better survival outcomes for the targeted patient group.

This interventional study employs a randomized, parallel assignment model without masking, focusing on treatment as its primary purpose. Participants are randomly assigned to either receive imetelstat or BAT, with the possibility of crossover to imetelstat if disease progression occurs under BAT.

The study began on April 12, 2021, and is currently recruiting participants. The last update was submitted on August 18, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.

The outcome of this study could significantly impact Geron Corporation’s stock performance and investor sentiment, especially if imetelstat proves to be more effective than existing therapies. This could position Geron favorably against competitors in the myelofibrosis treatment market.

The study is ongoing, with further details available on the ClinicalTrials portal.